Clinical trials: Dyskinesias
Psychomotor Agitation, Schizophrenia
A Study of Staccato Loxapine (ADASUVE®) for Inhalation
Phase 3 safety and efficacy study of Staccato Loxapine in the treatment of acute agitation in schizophrenic or bipolar disorder patients.
- Conditions
- Psychomotor Agitation, Schizophrenia, Bipolar Disorder
- Trial name
- NCT04148963
- Testing
- Inhaled loxapine
- Volunteers
- 150 people
- Sponsor
- Lee's Pharmaceutical Limited
Parkinson Disease
Performance of the Paragit Sleeve to Measure and Monitor Motor Symptoms in Patients With Parkinson's Disease
This investigation is undertaken to: Evaluate the accuracy and reliability of the device in measuring and recording motor symptoms associated with Parkinson's Disease (PD), and To assess the safety and tolerability of the device…
- Trial name
- PARPIV23 (NCT06490861)
- Testing
- Paragit
- Where
- Spain
- Volunteers
- 25 people
- Sponsor
- Paragit ApS
Ataxia-Telangiectasia, Ataxia-Telangiectasia (A-T)
A Pivotal Study of N-Acetyl-L-Leucine on Ataxia-Telangiectasia (A-T)
A pivotal, randomized, double-blind, placebo-controlled, multi-center therapeutic study for patients age 4 and older with a confirmed diagnosis of Ataxia-Telangiectasia (A-T).
- Trial name
- NCT06673056
- Testing
- N-Acetyl-L-Leucine
- Where
- 11 sites in United States, Germany and 4 more
- Volunteers
- 60 people
- Sponsor
- IntraBio Inc
Dyskinesia, Levodopa-Induced Dyskinesia (LID)
Efficacy and Safety Study of ADS-5102 in PD Patients With Levodopa-Induced Dyskinesia
This is a multi-center, randomized, double-blind, placebo-controlled, 2-arm, parallel group study to evaluate the efficacy and safety of ADS-5102 extended release (ER) capsules, an investigational formulation of amantadine, dosed…
- Conditions
- Dyskinesia, Levodopa-Induced Dyskinesia (LID), Parkinson's Disease (PD)
- Trial name
- EASE LID 3 (NCT02274766)
- Testing
- ADS-5102
- Where
- 51 sites in United States, Austria and 3 more
- Volunteers
- 77 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Cervical Dystonia
Study to Assess the Efficacy and Safety of Dysport® in Cervical Dystonia
The aim is to demonstrate equivalent efficacy and safety in the treatment of the two most frequent forms of cervical dystonia (predominantly rotational torticollis and predominantly laterocollis) with the standard initial dose of…
- Trial name
- NCT00447772
- Testing
- Botulinum toxin type A
- Where
- 106 sites in Austria, Germany
- Volunteers
- 516 people
- Sponsor
- Ipsen
Dyskinesias
Open-Label Extension Study of ASTORIA
This current open-label extension (OLE) study (JM-010CS-OL) will explore the safety and tolerability of long-term administration of JM-010 of patients who completed 12-week treatment of Phase 2 (JM-010CS03) study.
- Trial name
- NCT05516875
- Testing
- JM-010
- Where
- 2 sites in Italy, Spain
- Volunteers
- 6 people
- Sponsor
- Contera Pharma A/S
Cervical Dystonia
Long Term Safety And Effectiveness Of Dysport® In Adults With Cervical Dystonia
The purpose of the protocol is to assess the long term safety of repeat treatment cycles of Dysport® 500 U using 2 mL dilution scheme for the treatment of Cervical Dystonia.
- Trial name
- NCT01753336
- Testing
- Botulinum toxin type A
- Where
- 41 sites in United States
- Volunteers
- 112 people
- Sponsor
- Ipsen
Cervical Dystonia
Post-marketing Surveillance of Administration of Botulinum Toxin Type B(NerBloc)-Investigation of the Clinical Condition in Patients With Change From Botulinum Toxin Type A
Investigation of the clinical condition in patients with cervical dystonia by Toronto Western Spasmodic Torticollis Scale (TWSTRS)
- Trial name
- NCT02175719
- Where
- 2 sites in Japan
- Volunteers
- 150 people
- Sponsor
- Eisai Co., Ltd.
Stroke, Dystonia
MyoSense- Automated Muscle Hypertonicity Classification System
It is often difficult to quantify and distinguish aspects of abnormal muscle tone due to neurological injury. This makes it difficult to evaluate therapies that aim to reduce the effects of abnormal muscle tone.
- Conditions
- Stroke, Dystonia, Cerebral Palsy
- Trial name
- NCT02076581
- Where
- United States
- Volunteers
- 53 people, healthy volunteers welcome
- Sponsor
- Great Lakes NeuroTechnologies Inc.
Torticollis (Spasmodic)
Dose-escalating Safety and Preliminary Efficacy of DaxibotulinumtoxinA for Injection in Cervical Dystonia
This is an open-label, dose-escalation study to assess the safety and preliminary efficacy of daxibotulinumtoxinA in subjects with isolated cervical dystonia (CD).
- Trial name
- NCT02706795
- Testing
- DaxibotulinumtoxinA
- Where
- 13 sites in United States
- Volunteers
- 37 people
- Sponsor
- Revance Therapeutics, Inc.
Agitation Associated With Alzheimer's Dementia, Alzheimer Dementia
A Trial to Evaluate the Safety, Efficacy, and Tolerability of Brexpiprazole in Treating Agitation Associated With Dementia of the Alzheimer's Type
This study compares the efficacy of 2 doses of brexpiprazole with placebo in participants with agitation associated with dementia of the Alzheimer's type.
- Trial name
- NCT03548584
- Testing
- Brexpiprazole
- Where
- United States
- Volunteers
- 345 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary Ciliary Dyskinesia
Clearing Lungs With ENaC Inhibition in Primary Ciliary Dyskinesia
To evaluate the safety and efficacy of treatment with VX-371 with and without ivacaftor, and the effect of VX-371 with and without ivacaftor on quality of life (QOL) in subjects with primary ciliary dyskinesia (PCD).
- Trial name
- CLEAN-PCD (NCT02871778)
- Testing
- VX-371, Hypertonic Saline, VX-371 + HS
- Where
- 34 sites in United States, Canada and 6 more
- Volunteers
- 123 people
- Sponsor
- Parion Sciences
Parkinson Disease, Dyskinesia, Medication-Induced
AV-101 (L-4-chlorokynurenine) in Parkinson's Disease Subjects With Levodopa-Induced Dyskinesia
This is a randomized, double-blind, placebo-controlled, crossover, proof-of-concept Phase 2 study to test efficacy and safety of AV-101 (L-4-chlorokynurenine) in Parkinson's Disease subjects with levodopa-induced dyskinesia.
- Conditions
- Parkinson Disease, Dyskinesia, Medication-Induced, L-Dopa Causing Adverse Effects in Therapeutic Use
- Trial name
- NCT04147949
- Testing
- AV-101
- Volunteers
- 20 people
- Sponsor
- VistaGen Therapeutics, Inc.
Huntington Disease
An Extension of the HORIZON Protocol Evaluating the Safety of Dimebon (Latrepirdine) in Subjects With Huntington Disease
An open-label extension study of the HORIZON protocol evaluating the safety of dimebon (latrepirdine)in subjects with Huntington disease.
- Trial name
- HORIZON PLUS (NCT01085266)
- Testing
- Dimebon (latrepirdine)
- Volunteers
- 362 people
- Sponsor
- Medivation, Inc.
Parkinson Disease
Efficacy and Tolerability of IRL790 in Parkinson's Disease Dyskinesia
Mesdopetam (IRL790) is an experimental small molecule compound with psychomotor stabilizing properties. The primary target is the dopamine D3 receptor, a target implicated in the generation of levodopa-induced dyskinesia, a…
- Trial name
- NCT03368170
- Testing
- Mesdopetam (IRL790)
- Where
- 20 sites in Sweden, United Kingdom
- Volunteers
- 75 people
- Sponsor
- Integrative Research Laboratories AB
Cervical Dystonia
Open Label Safety/Immunogenicity Study of MYOBLOC (Neurobloc; Botulinum Toxin Type B) in Patients With Cervical Dystonia
Open label study to evaluate the safety and immunogenicity of MYOBLOC (Botulinum Toxin Type B) in adult patients with a clinical diagnosis of Cervical Dystonia (CD).
- Trial name
- NCT00702754
- Testing
- Botulinum Toxin Type B
- Volunteers
- 502 people
- Sponsor
- Solstice Neurosciences, LLC, a subsidiary of US WorldMeds, LLC
Parkinson Disease
Study to Evaluate the Efficacy, Safety, and Tolerability of PXT002331 (Foliglurax) in Reducing Levodopa-Induced Dyskinesia and Wearing OFF in Subjects With Parkinson's Disease Experiencing Motor Complications of Levodopa Therapy (ATTUNED)
This is a Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-arm Phase IIa proof of concept in subjects with PD treated with a stable dose of levodopa who are experiencing Motor Complications of Levodopa Therapy
- Trial name
- ATTUNED (NCT03331848)
- Testing
- PXT002331 - 20mg
- Sponsor
- Prexton Therapeutics
Tardive Dyskinesia
Addressing Involuntary Movements in Tardive Dyskinesia
The purpose of this study is to determine whether fixed-doses of an investigational drug, SD-809 (deutetrabenazine), will reduce the severity of abnormal involuntary movements of tardive dyskinesia.
- Trial name
- AIM-TD (NCT02291861)
- Testing
- SD-809
- Where
- 106 sites in United States, Czechia and 4 more
- Volunteers
- 298 people
- Sponsor
- Auspex Pharmaceuticals, Inc.
Unverricht-Lundborg Disease
Brivaracetam as add-on Treatment of Unverricht-Lundborg Disease in Adolescents and Adults
The study will compare the efficacy and safety of brivaracetam with placebo in patients with Unverricht-Lundborg disease.
- Trial name
- NCT00357669
- Testing
- Brivaracetam 25 mg, Brivaracetam 50 mg
- Where
- 13 sites in Finland, France and 5 more
- Volunteers
- 50 people
- Sponsor
- UCB Pharma SA
Tardive Dyskinesia, Huntington Disease
Safety, Tolerability and Pharmacokinetic of Multiple-ascending Doses of LPM3770164 in Healthy Subjects
This is a single-center, randomized, double-blind, placebo-controlled, multiple-ascending doses trial to evaluate the safety, tolerability and pharmacokinetic of LPM3770164 sustained-release tablets orally administered in healthy…
- Trial name
- NCT06216054
- Testing
- LPM3770164 sustained release tablet, LPM3770164 sustained release tablet simulant
- Where
- China
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Luye Pharma Group Ltd.